OncoMatch/Colorectal Cancer (CRC)/MLH1
Colorectal Cancer (CRC)MLH1 Clinical Trials
MLH1 promoter hypermethylation — the most common cause of sporadic dMMR CRC — silences MLH1 expression in approximately 10–15% of colorectal cancers and confers MSI-H status. MLH1/PMS2 co-loss is the typical IHC pattern for sporadic dMMR, predicting response to checkpoint immunotherapy. Pembrolizumab monotherapy is the first-line standard of care for MLH1-deficient/dMMR metastatic CRC.
Top recruiting MLH1 Colorectal Cancer (CRC) trials
Ranked by phase and US site count.
See all trials matched to your profile →Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer
National Cancer Institute, Naples
Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients
Sun Yat-sen University
PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer
Sun Yat-sen University
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Marengo Therapeutics, Inc.
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
Memorial Sloan Kettering Cancer Center
A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer
Criterium, Inc.
More MLH1 Colorectal Cancer (CRC) trials
16 international trials (no US sites)
Browse other molecular targets with active Colorectal Cancer (CRC) trials.